Shares of Coherus Biosciences Inc CHRS were trading down more than 15 percent on Monday following news that the Patent Trials and Appeals Board didn't institute their Intellectual Property Rights (IPR) '166 over Abbvie’s Humira.
Amid the price action, Citi analyst Mohit Bansal advised investors in a note that the institution of the ‘166 patent IPR isn't core to Citi’s thesis regarding Coherus and that investors should “buy on weakness.”
Bansal maintained a Buy rating and $36 price target for the stock.
"While this is being seen as a negative for CHRS, we note that our checks with patent experts did not suggest this patent was a key obstacle against a Humira biosimilar," said Bansal.
At time of writing, shares of Coherus were trading down around 11.5 percent at $24.90.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.